Proposed Changes to Medical Device Assessment Could Reshape Authorization Requirements

Thailand is reviewing proposed changes to how medical devices are assessed during the authorisation process.

On 13 August 2026, the Thai Food and Drug Administration (Thai FDA), through its Medical Device Control Division, published a draft announcement on the criteria, procedures, and conditions for assessing technical documents, analytical testing, establishment inspections, and other examinations used when considering medical-device authorisation.

The proposal is part of Thailand's ongoing development of its medical-device regulatory framework and could have practical implications for manufacturers and applicants preparing products for the Thai market.

What's Being Proposed?

The draft focuses on how different types of evidence and regulatory assessment may be used when the Thai FDA reviews authorisation applications. Areas specifically referenced include:

• Technical-document assessment

• Analytical or laboratory testing

• Establishment inspections

• Other examinations or verification activities relevant to authorisation

The proposal is identified as an amendment to the existing framework referred to by the Thai FDA as No. 2 (ฉบับที่ ๒).

Why this matters: authorisation isn't based solely on submitting a technical dossier. Depending on the product and circumstances, the authority may also assess supporting evidence, testing, or information about the manufacturing or establishment environment.

Regulatory Status: Still a Draft

At this stage, manufacturers should treat this as a proposal under review, not a binding requirement.

The Thai FDA opened consultation on the drafting principles from 13 July to 11 August 2026, followed by the draft announcement on 13 August 2026. Since it hasn't been presented as a final, effective announcement, companies shouldn't assume the draft provisions are already mandatory.

That said, the draft is a meaningful signal of where Thailand's medical-device assessment framework may be heading.

Why This Matters for Manufacturers

Regulatory predictability is a key part of market-entry planning. Changes to how documentation, testing, and establishment information are assessed can affect:

Area Potential Impact

• Submission preparation Technical evidence may need to be organised to support the assessment process and withstand requests for additional information

• Testing strategy Companies may need to consider what testing evidence exists, where it was conducted, and whether it's acceptable for the intended pathway

• Manufacturing-site readiness Establishment inspections mean readiness may extend beyond the dossier documentation, and quality systems may need to support inspection or verification.

• Regulatory timelines Additional assessment activities can affect how an application progresses; understanding requirements early helps reduce avoidable gaps

What Companies Should Watch

The Thai FDA continues to update requirements across several areas of medical-device regulation. Recent 2026 developments include updates on recognised experts and organisations responsible for technical-document assessment, alongside consultations on medical-device assessment and other requirements.

On 17 September 2026, the Thai FDA also published the **23rd edition of its list of experts and organisations, Thai and overseas, government and private, that may perform technical-document assessment functions for medical devices.

Together, these developments point to continued work on the mechanisms supporting regulatory assessment in Thailand.

What This Could Mean for Market Entry

Planning a Thai registration means preparing more than just the core technical file. Consider reviewing:

1. Technical documentation

Ensure your file is complete, internally consistent, and capable of supporting your intended authorisation pathway.

2. Testing evidence

Identify available testing and analytical evidence, and assess whether additional evidence could be required.

3. Manufacturing information

Review establishment information, quality-system documentation, and manufacturing records in case of potential inspection or verification.

4. Local regulatory coordination

Work closely with your Thai regulatory representative or local partner to track how the draft develops and whether further implementation guidance is issued.

5. Regulatory intelligence

Monitor the Thai FDA for the final announcement and any subsequent guidance and avoid changing procedures based solely on the draft.

ARQon Insight

Thailand's latest proposal highlights a core principle of medical-device market access: regulatory readiness begins before the application is submitted.

A technically complete dossier is only part of a successful authorisation strategy. Manufacturers also need to understand how the regulator may evaluate the evidence behind the product, including technical documentation, testing, and, where applicable, establishment information.

For companies preparing to enter Thailand, tracking this draft can help surface documentation and compliance gaps before final requirements take effect. But because the proposal is still a draft, it's equally important to distinguish between current legal obligations and potential future requirements.

What Manufacturers Should Do Now

While the final position is pending, companies considering Thailand can:

• Review existing medical-device technical documentation

• Map available testing and analytical evidence against the intended registration pathway

• Review manufacturing-site and quality-system documentation

• Identify potential gaps that could require additional evidence.

• Coordinate with their Thai regulatory representative or local partner

• Monitor Thai FDA announcements for the final version and implementation details.

  
  

Key Takeaway

Thailand is continuing to develop its medical-device assessment framework, with the Thai FDA's August 2026 draft proposing updated criteria and procedures covering technical-document assessment, analytical testing, establishment inspections, and other examinations tied to authorisation.

The proposal is not yet a final binding requirement, but it's an important development for manufacturers planning or maintaining market access in Thailand.

Early regulatory intelligence can turn potential changes into manageable preparation, rather than last-minute compliance work.

How ARQon Can Support You

• Regulatory intelligence and monitoring

• Thailand market-entry strategy

• Medical-device registration planning

• Technical documentation gap assessment

• Local representative coordination

• Cross-border market-access strategy

Stay Ahead. Stay Compliant. Stay Informed.

With ARQon Regulatory Intelligence.

Source

Thailand Food and Drug Administration Medical Device Control Division: regulatory laws, standards, and consultation notices.